DAX-0,09 % EUR/USD+0,09 % Gold-0,41 % Öl (Brent)-1,47 %

Omnicell and Kit Check Partner to Offer Cloud-based Solution for Tracking of Controlled Substances

Nachrichtenquelle: Business Wire (engl.)
09.12.2019, 14:01  |  104   |   |   

Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, has entered into an agreement with Kit Check to offer Bluesight for Controlled Substances diversion prevention software, helping customers to gain better visibility of controlled substances across the pharmacy supply chain.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005247/en/

According to the Association of Healthcare Internal Auditors, the estimated cost of controlled prescription drug diversion and abuse to both public and private medical insurers is approximately $72.5 billion a year.1 Despite being the hardest hit by diversion, many health systems lack the necessary tools to detect these incidences in real time.

Through this new partnership, Omnicell customers will have access to a single sign-on dashboard that aggregates information from automated dispensing cabinets and the EMR, documenting who is handling what medications, when, where, and for whom. Using industry-leading data science techniques, Bluesight for Controlled Substances analyzes behavior patterns within peer groups—including time lags, movement, wasting relationships, and more—and then distills problem areas and individuals into a focused action list of Individual Risk Identification Scores (IRIS).

“It’s imperative that we give Pharmacy the insights to help combat the growing crisis of diversion and opioids,” said Nhat Ngo, executive vice president, Marketing, Strategy, and Business Development at Omnicell. “Building technology partnerships with companies like Kit Check will be key to driving solutions for one of the biggest problems in healthcare today.”

Bluesight for Controlled Substances consolidates charting and dispensing documentation, highlighting risk and deviations from the norm as they occur, reported through easy-to-navigate dashboards. All analytics and dashboards are updated in real-time with every data transfer, supporting quick identification of outliers or patterns.

“We’re proud to partner with Omnicell to offer Bluesight for Controlled Substances to even more hospitals and pharmacies across the United States and beyond,” said Kevin MacDonald, CEO and co-founder of Kit Check. “With diversion being a top concern across the healthcare continuum, our cutting-edge diversion identification technology provides unparalleled visibility and medication intelligence to ensure the right person is getting the right drug at the right time. As the only two technology vendors designated as ‘next generation’ by KLAS in its recent Drug Diversion Monitoring report, I am confident that this collaboration will significantly advance the market, the organizations we serve and the medical professionals they employ.”

Seite 1 von 2
Omnicell Aktie jetzt für 4€ handeln - auf Smartbroker.de

Diesen Artikel teilen

Mehr zum Thema
Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Aus der Community
LUS Wikifolio-Index Performance von Kryptowährungen Index Zertifikat Open-End (LASW)
Chart: arniarni

Meistgelesene Nachrichten des Autors


Diskussionen zu den Werten